Windward Bio - About the company
Windward Bio is a series B company based in Basel (Switzerland), founded in 2020 by Luca Santarelli, Luca Santarelli and Luca Santarelli. It operates as a Company develops monoclonal antibody therapeutics for immunological and respiratory diseases. Windward Bio has raised $365M in funding from investors like Orbimed, Blue Owl and Novo Holdings. The company has 42 active competitors, including 12 funded and 10 that have exited. Its top competitors include companies like Generate Biomedicines, Innoviva and RAPT.
Company Details
Company develops monoclonal antibody therapeutics for immunological and respiratory diseases. It focuses on advancing a thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development. It also creates novel, long-acting bispecific programs for immunological diseases. The company's lead candidate, WIN378, is a fully human monoclonal antibody engineered for extended half-life and effector silencing, targeting the TSLP ligand to treat asthma, COPD, and other inflammatory phenotypes.
- Website
- windwardbio.com
- Email ID
- *****@windwardbio.com
Key Metrics
Founded Year
2020
Location
Basel, Switzerland
Stage
Series B
Total Funding
$365M in 2 rounds
Latest Funding Round
Ranked
6th among 42 active competitors
Employee Count
49 as on Aug 31, 2026
Similar Companies
Sign up to download Windward Bio's company profile
Windward Bio's funding and investors
Windward Bio has raised a total funding of $365M over 2 rounds. Its first funding round was on Jan 10, 2025. Its latest funding round was a Series B round on May 04, 2026 for $*****. 12 investors participated in its latest round. Windward Bio has 16 institutional investors.
Here is the list of recent funding rounds of Windward Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 04, 2026 | 1377025 | Series B | 1685102 | 3263107 | 8506128 | 9811043 |
Jan 10, 2025 | 4615030 | Series A | 1153268 | 4959093 |
Access funding benchmarks and valuations. Sign up today!View details of Windward Bio's funding rounds and investors
Windward Bio's founders and board of directors
Founder? Claim ProfileThe founders of Windward Bio are Luca Santarelli, Luca Santarelli and Luca Santarelli. Luca Santarelli, Luca Santarelli and Luca Santarelli are the CEOs of Windward Bio.
Here are the details of Windward Bio's key team members:
- Luca Santarelli: Founder, CEO and Chairman of Windward Bio.
- Luca Santarelli: Founder & CEO of Windward Bio.
- Luca Santarelli: Founder, CEO and Chairman of Windward Bio.
View details of Windward Bio's Founder profiles and Board Members
Windward Bio's employee count trend
Windward Bio has 49 employees as of Aug 26. Here is Windward Bio's employee count trend over the years:
Uncover Windward Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Windward Bio's Competitors and alternates
Top competitors of Windward Bio include Generate Biomedicines, Innoviva and RAPT. Here is the list of Top 10 competitors of Windward Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Generate Biomedicines 2018, Somerville (United States), Public | Developer of a platform for generating novel protein-based therapeutic modalities | $693M | 66/100 | |
2nd | _1548323159420.png?devicePixelRatio=2&height=30&width=30){kind=logo} Innoviva 1996, Brisbane (United States), Public | Manufacturer of respiratory-based generic drugs | - | 61/100 | |
3rd |  RAPT 2015, San Francisco (United States), Acquired | Provider of immunology-based drug for oncology and inflammatory diseases | $199M | 59/100 | |
4th |  Recludix Pharma 2020, San Diego (United States), Series A | Provider of the online platform for drug discovery and development | $60M | 59/100 | |
5th | Accropeutics 2017, Suzhou (China), Series C | Developer of drugs for inflammation, autoimmune diseases, and cancer | $62M | 59/100 | |
6th |  Windward Bio 2020, Basel (Switzerland), Series B | Company develops monoclonal antibody therapeutics for immunological and respiratory diseases | $365M | 57/100 | |
7th | Developer of antibody-based therapeutics to treat various diseases | $76.4M | 56/100 | ||
8th |  Ena Respiratory 2020, Melbourne (Australia), Series B | Developer of antiviral host defense enhancers for respiratory infections. It develops first-in-class prophylactics that prime and boost the body's natural defenses against viral respiratory infections. These enhancers have demonstrated effectiveness against various viruses in preclinical and clinical studies. A lead product is being developed as a convenient, weekly nasal product for self-administration, addressing a significant medical need in at-risk populations. The company has secured funding and partnerships to advance clinical development and pandemic preparedness efforts. | $52.4M | 55/100 | |
9th |  ASLAN Pharmaceuticals 2010, Singapore (Singapore), Public | Targeted small molecules for cancer treatment | $100M | 54/100 | |
10th |  Forte Biosciences 2017, Torrance (United States), Acquired | Developer of therapeutic solutions for treating inflammatory skin diseases | - | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Windward Bio's competitors? Click here to see the top ones
Windward Bio's Investments and acquisitions
Windward Bio has made no investments or acquisitions yet.
Reports related to Windward Bio
Here is the latest report on Windward Bio's sector:
News related to Windward Bio
Media has covered Windward Bio for a total of 9 events in the last 1 year, 3 of them have been about company updates.
•
Harbour BioMed Announces Positive Phase 2 Results for HBM9378/WIN378 in Asthma, Initiates Phase 3 StudyPR Newswire•Sep 08, 2026•Windward Bio, Harbour BioMed
•
Windward Bio doses first patients in Phase II SIRIUS COPD trialHospital Management•Jun 10, 2026•Windward Bio
•
Accro Bioscience Secures $50M Series C Funding Led by OrbiMed for Immune Disease TherapiesPR Newswire•May 19, 2026•Accropeutics, Orbimed, LAV, Oriza Holdings and 4 others
•
Windward Bio Secures $165 Million to Advance Asthma Drug into Phase 3 TrialEndpoints•May 04, 2026•Windward Bio, RTW Investments, RB Capital, Orbimed and 1 other
•
Kelun-Biotech Announced 2025 Annual Results: Multiple Products Successfully Launched with Tiered Pipeline Ready for Take-OffPR Newswire•Mar 23, 2026•Kelun Biotech, Merck Sharp & Dohme, Ellipses Pharma, Windward Bio and 1 other
•
Windward Bio to acquire Qyuns bispecific for up to $700M in second China dealEndpoints•Dec 22, 2025•Windward Bio, Qyuns Therapeutics
•
Windward Bio launches Phase II trial of asthma treatmentclinicaltrialsarena.com•Jul 24, 2025•Windward Bio
•
Windward Bio Group AG’s $200 Million Series A Financing RoundGlobal Legal Chronicle•Jan 24, 2025•Homburger, Ropes & Gray, RTW Investments, Windward Bio
•
Windward Bio Raises $200M in FundingFinSMEs•Jan 13, 2025•Windward Bio, Pivotal Life Sciences, Quan Capital, Qiming Venture Partners and 8 others
•
Harbour BioMed licenses antibody drug HBM9378/SKB378 for immunological diseases.PR Newswire•Jan 10, 2025•Harbour BioMed, Windward Bio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Windward Bio
Explore our recently published companies
- Hallway Talk - Denver based, 2014 founded, Unfunded company
- Shalom Hills - Gurugram based, 2004 founded, Unfunded company
- The Space Station - Unfunded company
- Ralph van Roosmalen - Unfunded company
- Universidad Virtual Hispanica de Mexico - Mexico based, Unfunded company
- BRANDOW'S FEED & SEED - Oneonta based, 2005 founded, Unfunded company
